Human epidermal growth factor receptor negative – Diagnostics – Overview of Information and Clinical Research

Human epidermal growth factor receptor negative (HER2-negative) is a classification used in breast cancer diagnosis that helps doctors understand the biology of the tumor and choose the most appropriate treatment approach. Understanding whether a breast cancer is HER2-negative or HER2-positive is crucial for determining which therapies will work best for each individual patient.

Introduction: Who Should Undergo Diagnostics

When breast cancer is suspected or diagnosed, testing for HER2 status—meaning whether the cancer cells have too many human epidermal growth factor receptor 2 proteins—is a standard and essential part of the diagnostic process. Every person diagnosed with breast cancer should undergo HER2 testing, as this information directly influences treatment decisions and helps predict how the cancer might behave.^[1]^[11]

The HER2 receptor is a protein that sits on the surface of breast cells and normally helps control how cells grow, divide, and repair themselves. In healthy tissue, this process works smoothly. However, in some breast cancers, the HER2 gene malfunctions and creates too many copies of itself. This leads to an overproduction of HER2 proteins, which causes cancer cells to grow and spread more aggressively. When a breast cancer does not have this overproduction of HER2 proteins, it is called HER2-negative.^[2]^[14]

Most breast cancers fall into the HER2-negative category. In fact, about four out of five breast cancers do not have extra HER2 proteins, making HER2-negative breast cancer the most common form of the disease. This classification matters greatly because HER2-negative cancers typically have a better outlook than HER2-positive ones, since they tend to be less aggressive. However, knowing the HER2 status is just one piece of the puzzle—doctors also look at other characteristics of the cancer to build a complete picture.^[14]^[19]

Testing for HER2 status becomes especially important when deciding on treatment options. Certain targeted therapies work specifically against cancers with high levels of HER2 proteins. If a cancer is HER2-negative, these particular treatments will not be effective, and doctors will recommend different therapeutic approaches instead. This is why accurate testing is so critical—it prevents patients from receiving treatments that won’t help them and ensures they get therapies that are more likely to work.^[14]

Diagnostic Methods: Classic Testing Approaches

Determining whether a breast cancer is HER2-negative requires laboratory testing on a sample of the tumor tissue. Doctors cannot tell the HER2 status by physical examination alone, as HER2-negative and HER2-positive breast cancers cause the same symptoms. The tissue sample needed for testing is obtained either through a biopsy—a procedure where a small piece of tissue is removed using a needle or during surgery—or from tissue taken during surgical removal of the tumor.^[14]^[18]

Once the tissue sample reaches the laboratory, specialized tests are performed to measure the amount of HER2 protein present in the cancer cells or to count how many copies of the HER2 gene exist. There are several different testing methods available, but two are most commonly used: the IHC test and the FISH test. Each provides different types of information about the HER2 status, and sometimes both tests are needed to get a clear answer.^[18]

The IHC Test

The IHC test, which stands for ImmunoHistoChemistry, is often the first test performed. This test uses special chemical dyes that attach to and stain the HER2 proteins on the surface of cancer cells. The amount of staining is then measured and given a score from 0 to 3+. This score reflects how much HER2 protein is present in the tissue sample.^[18]

When the IHC test results come back as 0 or 1+, the cancer is considered HER2-negative. These scores mean that very little or no extra HER2 protein was found. A score of 2+ is called borderline or equivocal, meaning the result is unclear. In these cases, additional testing with a FISH test is usually performed to get a definitive answer. Only when the score reaches 3+ is the cancer classified as HER2-positive, indicating high levels of HER2 protein on the cell surface.^[18]

The FISH Test

The FISH test, short for Fluorescence In Situ Hybridization, works differently from the IHC test. Instead of measuring HER2 proteins on the cell surface, the FISH test looks directly at the HER2 genes inside the cell nucleus. It uses special fluorescent labels that attach to the HER2 genes themselves, making them visible under a microscope. The laboratory technician can then count how many copies of the HER2 gene are present in each cell.^[18]

If the FISH test shows a normal number of HER2 gene copies, the cancer is classified as HER2-negative. If the test reveals many extra copies of the gene, the cancer is HER2-positive. The FISH test is particularly useful when IHC results are borderline, as it provides a more direct measurement of the genetic abnormality that drives HER2 overproduction.^[18]

Understanding HER2-Low and HER2-Ultralow

Recent developments in testing have revealed that the simple division between HER2-negative and HER2-positive may not tell the whole story. Many cancers that are technically classified as HER2-negative actually have small amounts of HER2 protein on their cells—just not enough to be called HER2-positive. Doctors now sometimes refer to these cancers as HER2-low or HER2-ultralow. This distinction is becoming increasingly important as new treatments are developed that might work for patients with these intermediate levels of HER2 expression.^[18]

⚠️ Important

Breast cancers can change their characteristics over time or if they come back after treatment. A cancer that was originally HER2-negative might become HER2-positive later, or vice versa. If breast cancer returns or spreads, doctors should consider repeating HER2 testing to ensure treatment decisions are based on current information about the cancer.^[14]^[18]

The Complete Picture: Combining HER2 Status with Hormone Receptor Testing

HER2 testing is almost always performed alongside testing for hormone receptors. Hormone receptors include estrogen receptors (ER) and progesterone receptors (PR), which are proteins that respond to hormones in the blood. When breast cancer cells have these receptors, the cancer can be fueled by hormones like estrogen or progesterone. Testing for hormone receptors helps doctors understand the complete biology of the cancer.^[14]^[19]

Doctors often describe breast cancer by combining the HER2 status with the hormone receptor status. A HER2-negative cancer can be either hormone receptor-positive (HR+/HER2-) or hormone receptor-negative (HR-/HER2-). The most common type is HR+/HER2-, which accounts for almost 70% of all breast cancers. When a cancer is negative for HER2 and both types of hormone receptors, it is called triple-negative breast cancer, which makes up about 10 to 15% of cases.^[7]^[14]^[19]

This combined information—HER2 status plus hormone receptor status—tells doctors a great deal about how the cancer is likely to behave and which treatments are most likely to be effective. For instance, HR+/HER2- cancers often respond well to hormone-based therapies, while triple-negative cancers require different treatment approaches entirely. Each combination creates a unique profile that guides personalized treatment planning.^[7]^[8]

Diagnostics for Clinical Trial Qualification

When patients are being considered for participation in clinical trials studying new breast cancer treatments, thorough and accurate diagnostic testing becomes even more important. Clinical trials are research studies that test whether new treatments are safe and effective. These studies have strict eligibility requirements, and confirming the HER2 status is typically one of the most fundamental criteria for enrollment.^[7]

For clinical trials focusing on HER2-negative breast cancer, potential participants must have documentation of their HER2 status through standardized testing methods. This usually means having results from both IHC and sometimes FISH testing performed according to established laboratory guidelines. The testing must be done at a certified laboratory to ensure accuracy and reliability of the results.^[7]

In addition to HER2 testing, clinical trials often require comprehensive testing of hormone receptor status. For trials specifically targeting HR+/HER2- breast cancer—the most common subtype—patients must have documented evidence that their cancer is positive for estrogen or progesterone receptors but negative for HER2. This ensures that the experimental treatment being studied is tested in the right patient population, where it is most likely to show benefit.^[7]^[8]

Some clinical trials are now investigating treatments for the newly recognized HER2-low category of breast cancer. For these studies, more precise testing may be required to distinguish between true HER2-negative cancers and those with low levels of HER2 expression. This might involve repeat testing or additional specialized testing methods to accurately categorize the cancer and determine if a patient is eligible for these specific trials.^[18]

Beyond HER2 and hormone receptor testing, clinical trials may require additional diagnostic procedures to establish baseline health status and ensure patient safety. These can include imaging tests such as CT scans or MRI scans to determine the extent of cancer spread, blood tests to assess overall health and organ function, and biopsies to collect fresh tissue for more detailed analysis. Some trials are also investigating genetic markers within tumors, which requires specialized molecular testing on tumor samples.^[7]

For patients with HR+/HER2- metastatic breast cancer—cancer that has spread to other parts of the body—clinical trials often test combinations of treatments. These might include endocrine therapies combined with targeted agents or newer classes of drugs. Qualification for such trials typically requires not only confirmation of HER2-negative and hormone receptor-positive status, but also documentation of disease progression or resistance to previous therapies. This ensures that the experimental treatments are tested in patients who might benefit most from novel approaches.^[8]^[10]

⚠️ Important

Participation in clinical trials offers patients access to promising new treatments before they become widely available. However, the strict diagnostic requirements exist to protect patient safety and ensure that research results are accurate and meaningful. Patients interested in clinical trials should discuss their diagnostic test results thoroughly with their healthcare team to understand which trials they might be eligible for.^[7]

Prognosis and Survival Rate

Prognosis

The outlook for patients with HER2-negative breast cancer varies considerably depending on several important factors, including the stage at diagnosis, whether the cancer is also positive or negative for hormone receptors, the grade of the tumor, and how well the cancer responds to treatment. Generally speaking, HER2-negative breast cancers tend to have a more favorable prognosis compared to HER2-positive cancers, as they are typically less aggressive and grow more slowly.^[14]^[19]

Among HER2-negative cancers, those that are hormone receptor-positive (HR+/HER2-) often have the best outcomes, particularly when detected early. These cancers usually respond well to hormone-based therapies, which can be taken for several years to reduce the risk of recurrence. However, HR+/HER2- cancers can have a longer window of recurrence risk—sometimes extending many years after initial treatment—compared to other breast cancer subtypes. Studies have shown that recurrence risk can range from 13 to 41% over a 20-year period even after completing five years of endocrine therapy.^[7]

For patients with advanced or metastatic HR+/HER2- breast cancer—meaning the cancer has spread to other parts of the body—the prognosis becomes more challenging. While treatments can control the disease for extended periods, metastatic breast cancer is generally not curable with current therapies. Research indicates that the average five-year survival rate for patients with advanced and metastatic HR+/HER2- breast cancer is approximately 34%, which is considerably lower than the 94.8% five-year survival rate for all HR+/HER2- breast cancer patients combined, including those diagnosed at early stages.^[7]

Triple-negative breast cancers (those that are HER2-negative, estrogen receptor-negative, and progesterone receptor-negative) present unique challenges. These cancers tend to be more aggressive and have fewer targeted treatment options available, as they do not respond to hormone therapies or HER2-targeted treatments. However, when triple-negative cancers do respond well to chemotherapy, particularly in the early stages, patients can achieve excellent outcomes. The key is early detection and aggressive initial treatment.^[13]^[15]

Several factors can influence prognosis beyond HER2 status itself. Age at diagnosis, overall health, the presence of other medical conditions, and how well a patient tolerates treatment all play important roles in determining outcomes. Additionally, access to comprehensive care, including specialized breast cancer centers, supportive services, and newer treatment options through clinical trials, can significantly impact long-term survival and quality of life.^[17]

Survival rate

Survival rates for HER2-negative breast cancer have improved substantially over the past several decades due to advances in early detection through screening mammography, better surgical techniques, more effective systemic therapies, and improved supportive care. However, survival statistics vary widely depending on the specific characteristics of each patient’s cancer and when it is detected.^[7]

For all patients with HR+/HER2- breast cancer—the most common subtype of HER2-negative cancer—the overall five-year survival rate is approximately 94.8% when all stages are considered together. This relatively high survival rate reflects the fact that many of these cancers are detected early through screening programs when they are still confined to the breast and have not spread to lymph nodes or distant organs. Early-stage HR+/HER2- cancers have excellent survival rates, often exceeding 95% at five years.^[7]

However, survival rates drop significantly for advanced disease. When HR+/HER2- breast cancer has spread to distant parts of the body (metastatic disease), the five-year survival rate falls to approximately 34%. This dramatic difference underscores the critical importance of early detection and the need for continued research into more effective treatments for advanced disease. Many clinical trials are actively studying new treatment combinations and novel therapies specifically for patients with metastatic HR+/HER2- breast cancer.^[7]^[8]

It is important to understand that survival statistics represent averages across large populations and may not predict outcomes for any individual patient. Many factors influence how long someone might live with breast cancer, including the specific biology of their tumor, their response to treatment, their overall health, and advances in therapy that occur after statistics are calculated. Additionally, survival rates continue to improve over time as new treatments become available, meaning that current patients may have better outcomes than what older statistics suggest.^[7]

For patients interested in understanding their personal prognosis, it is essential to have detailed discussions with their oncology team. Doctors can consider the complete picture—including stage, grade, hormone receptor status, response to treatment, and individual health factors—to provide more personalized estimates of outcomes and help patients make informed decisions about their care.^[17]

#1 Clinical Trials Search in Europe